Roche’s Ocrelizumab Poised To Seize Primary Progressive MS Opportunity
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche plans to file the selective CD20 antibody in 2016 after releasing positive Phase III data at ECTRIMS in both relapsing-remitting and primary progressive multiple sclerosis, a debilitating form of the disease for which there are no approved drugs.